Last reviewed · How we verify
Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)
Details
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 100 |
| Start date | Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Immune Thrombocytopenia
Interventions
- Iguratimod
Countries
China